Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AdociaLTS:0QAI +1.41%40 Debt-to-Equity is 5.97 as of Dec. 2025, which is 4492% above its 10-year median of 0.13. GuruFocus rates LTS:0QAI with a GF Score™ of 40/100 and a GF Value™ of €0.88 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 965 Biotechnology companies, Adocia ranks worse than 98.03% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Adocia's Debt-to-Equity or its related term are showing as below:
LTS:0QAI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -2.77 Med: 0.13 Max: 5.97
Current: 5.97
During the past 13 years, the highest Debt-to-Equity Ratio of Adocia was 5.97. The lowest was -2.77. And the median was 0.13.
LTS:0QAI's Debt-to-Equity is ranked worse than 98.03% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs LTS:0QAI: 5.97
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Adocia Debt-to-Equity Related Terms
Adocia Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Adocia's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QAI vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Adocia's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adocia Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adocia's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Adocia's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adocia (LTS:0QAI) has a Debt-to-Equity of 5.97 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Adocia and its competitors. This is 4492% above median its historical median of 0.13. According to the industry distribution chart, Adocia ranks #946 out of 965 companies in the Biotechnology industry, placing it in the top 98%.
Is Adocia's Debt-to-Equity too high?
Adocia's current Debt-to-Equity of 5.97 is 4492% above median its 10-year median of 0.13. The Biotechnology industry median Debt-to-Equity is 0.16. Adocia's value of 5.97 is 3631.3% above this industry median. Based on the distribution chart, Adocia ranks #946 out of 965 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adocia has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adocia's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Adocia ranks #946 out of 965 companies for Debt-to-Equity. This places Adocia in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Adocia's value of 5.97 is 3631.3% above this benchmark. While the company's 10-year median is 0.13 vs. the industry median of 0.16, Adocia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adocia's current Debt-to-Equity of 5.97 is 3631.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Adocia and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adocia's current Debt-to-Equity is 5.97, which is 4492% above median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adocia stock overvalued right now?
Based on GuruFocus' analysis, Adocia (LTS:0QAI) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.88, compared to a current price of €3.87 — trading 340% above its estimated fair value. The current Debt-to-Equity is 5.97, which is 4492% above median its 10-year median of 0.13 and 3631.3% above the Biotechnology industry median of 0.16. Adocia's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Adocia (LTS:0QAI), the current Debt-to-Equity is 5.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adocia (LTS:0QAI) Overvalued in 2026?
Based on GuruFocus' analysis, Adocia stock appears to be overvalued.
The current stock price of €3.87 is trading 340% above its estimated GF Value™ of €0.88.
GuruFocus considers Adocia to be Significantly Overvalued.
Key valuation signals for LTS:0QAI:
Debt-to-Equity: 5.97 (4492% above median its 10-year median of 0.13)
GF Value™: €0.88 vs. price of €3.87 (340% above fair value)
Industry Position: 3631.3% above the Biotechnology median (#946 of 965)
No single metric tells the full story. See the LTS:0QAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.
40GF Score
Get the complete analysis for LTS:0QAI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QAI has been successfully added to your 
